Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Maryland, Baltimore
With
National Institute of Mental Health (NIMH)
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DSM-IV diagnosis of schizophrenia or schizoaffective disorder
Male or Female
Age: 18 to 65 years
Caucasian or Non-Caucasian
At least six months of clozapine treatment
Clozapine treatment for incomplete symptoms response (evidence of two failed previous trials of antipsychotics)
Current dose of 200 mg/day for at least 3 months AND a documented clozapine blood level 350 ng/ml prior to study start (maximum clozapine dose of 900 mg/day)
BPRS total score of 45 or more on the 18 item version (scale: 1-7)
BPRS positive symptom item total score of 8 or more
BPRS positive symptom score of 4 or greater on at least one item
You may not be if
History of organic brain disease
DSM-IV diagnosis of Mental Retardation
DSM-IV diagnosis of Alcohol or Substance Dependence within the last six months (except nicotine)
DSM-IV diagnosis of Alcohol or Substance Abuse within the last one month (except nicotine)
Pregnancy or lactation
Significant renal or liver impairment
Previous known hypersensitivity to tetracyclines
Current treatment with tetracycline or derivative
Current treatment with lamotrigine
Treatment with oral contraceptives
Current known infection
Treatment with cholestyramine or colestipol
Treatment with Urinary alkalinizers (e.g., sodium lactate, potassium citrate)
Treatment with warfarin
Abnormal (considered positive) Lyme titer
Clareo Health | Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients
